GLYCIPHAGE is an oral antidiabetic drug belonging to the biguanide group. GLYCIPHAGE overcomes insulin resistance and it has an extra-pancreatic peripheral action. It does not produce hypoglycaemia in normal subjects.
GLYCIPHAGE has fibrinolytic activity which has prophylactic and therapeutic value in various vascular complications of diabetes. e.g. Coronary artery disease, cerebrovascular accidents and peripheral vascular disease.
Type 2 diabetes patients not responding to dietary regulations and physical exercise, should be put on GLYCIPHAGE as the first line treatment.
- In IGT.
- In combination with insulin secretagogues, glitazones and adjuvant to insulin therapy.
- In PCOS.
- In essential hypertension.
GLYCIPHAGE 500 Tablets are available in a blister strip of 20 tablets, 10 such blister strips in a carton.
GLYCIPHAGE 850 Tablets and GLYCIPHAGE 250 Tablets are available in a blister strip of 10 tablets, 10 such blister strips in a carton.